H eart failure (HF) is the leading cause for hospital admission and readmission. 1, 2 Nearly half of the estimated 6 million HF patients in the United States have diastolic HF or HF with preserved ejection fraction (HFpEF). 1 The vast majority of HF patients are ≥65 years, most of who have HFpEF. 3 However, there is little randomized controlled trial (RCT) evidence to guide therapy for HFpEF patients. 4, 5 Calcium channel blockers (CCBs) have been hypothesized to be beneficial in patients with HFpEF. 4 In small studies, CCBs have been shown to improve HF score, exercise capacity, and diastolic function in HFpEF patients. 6, 7 However, the role of CCBs on clinical outcomes in HFpEF patients remains unclear. When RCT data are unavailable or it is impractical or unethical to conduct RCTs, propensity scorematched non-RCT studies based on retrospective outcomeblinded assembly of balanced cohorts may provide evidence in a timely and cost-effective manner. [8] [9] [10] [11] Therefore, in the current study, we examined the clinical effectiveness of CCBs in a propensity-matched cohort of older patients with HFpEF.
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Methods
Data Sources and Study Population
The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) is a national registry of hospitalized HF patients, the rationale and design has been described in detail, previously. [12] [13] [14] Briefly, charts of 48 612 hospitalizations due to HF or associated with HF in 259 hospitals in 48 US states were collected between March 2003 and December 2004. 12, 13 Charts with a primary discharge diagnosis of HF based on International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes were selected, regardless of whether a patient was hospitalized for decompensated HF or developed HF symptoms after admission for another admitting diagnosis. Data on baseline demographics, medical history, hospital course, and discharge dispositions were collected in detail. Because HF patients with EF 40% to 50% have similar clinical and prognostic characteristics than those with EF >50%, 15 we used EF cutoff ≥40% to define HFpEF. Of the 48 612 HF hospitalizations, 20 839 occurred in patients with HFpEF.
The OPTIMIZE-HF collected short-term outcome data only for a small subset of patients for 60 to 90 days. To obtain long-term outcome data, we linked OPTIMIZE-HF to Medicare data using 100% Medicare Provider Analysis and Review (MedPAR) File and 100% Beneficiary Summary File between January 1, 2002, and December 31, 2008 . Of the 20 839 HFpEF hospitalizations, we were able to link 13 270 hospitalizations to Medicare data that occurred in 11 997 unique patients. Of these, 10 889 were aged ≥65 years, and 10 570 were discharged alive. 16 OPTIMIZE-HF was approved by institutional review boards of the participating hospitals.
Assembly of an Eligible Cohort
Data on admission and discharge use of CCBs and other key HF medications such as angiotensin-converting enzyme inhibitors, angiotensin receptors blockers, aldosterone antagonists, and β-blockers were collected by chart abstraction. After excluding 146 patients with contraindications to the use of CCBs, such as patients having secondor third-degree atrioventricular block (n=33), and who had symptomatic hypotension defined as admission systolic blood pressure (BP) <90 mm Hg (n=113), the remaining 10 424 patients were considered eligible for CCB therapy.
Assembly of an Inception Cohort
Because prevalent drug use may cause bias by left censoring or by affecting baseline characteristics, [17] [18] [19] we assembled an inception cohort of patients who were not receiving prior CCB therapy. Therefore, we excluded 2910 patients receiving CCBs during hospital admission. Thus, the final sample size for our inception cohort consisted of 7514 patients, of whom 815 (11%) received a new discharge prescription for CCBs.
Assembly of a Balanced Cohort
To eliminate the imbalances in measured baseline characteristics because of selection bias associated with a discharge prescription of CCBs, we used propensity score or the probability of receiving a discharge prescription of CCBs to assemble a matched cohort of patients receiving and not receiving CCBs that would be well balanced on all measured baseline covariates. [8] [9] [10] Using nonparsimonious logistic regression model, we estimated propensity scores for each of the 7514 patients. [20] [21] [22] In this model, the receipt of CCB was the dependent variable and 114 baseline characteristics were used as covariates. Using a greedy matching protocol, we were then able to match 810 of the 815 patients receiving CCBs with another 810 patients not receiving them but had similar propensity to receive it. 23, 24 The effectiveness of propensity score model was assessed by estimating absolute standardized differences, and results were presented as a Love plot (Figure 1) . [25] [26] [27] Absolute standardized difference values <10% are considered inconsequential, and 0% indicates no residual bias.
Outcomes
The primary outcome for the current analysis was a composite end point of all-cause mortality or HF hospitalization during 6 years of follow-up (median, 2.7 years). Secondary outcomes were all-cause mortality, HF hospitalization, and all-cause hospitalization. As described earlier, all outcomes data were obtained from Medicare claims data. 16 regression and Kaplan-Meier analyses were used to determine associations of discharge prescriptions of CCBs with outcomes. Subgroup analyses were conducted to determine homogeneity of associations between CCB use and the primary composite end point. A formal sensitivity analysis was planned to estimate the degree of hidden bias that could potentially explain away a significant association among matched patients. 29 We then repeated our analyses in the prematch cohort using (1) unadjusted; (2) multivariable-adjusted, using all 114 baseline characteristics; and (3) propensity score-adjusted Cox regression models. We then compared matched patients receiving amlodipine and nonamlodipine CCBs (versus no CCBs). We repeated an above process to assemble second propensity-matched cohort using EF cutoff 50%. All statistical tests were 2-tailed with a P value <0.05 considered significant. SPSS for Windows version 21 (IBM Corp, Armonk, NY) was used for data analyses.
Results
Baseline Characteristics
Matched patients (n=1620) had a mean (±SD) age of 80 (±8) years, mean (±SD) left ventricular EF of 56% (±9), 65% were women, and 10% were black. Before matching, patients receiving a new prescription for CCBs were more likely to be younger, blacks, and had high left ventricular EF and higher prevalence of comorbidities, such as hypertension, chronic obstructive pulmonary disease, and peripheral vascular disease. They were also less likely to receive angiotensin-converting enzyme inhibitors, β-blockers, and aldosterone antagonists. These and other prematch imbalances were balanced after matching (Table 1; Figure 1 ). Absolute standardized differences for most of the baseline characteristics between the 2 treatment groups were <10%, suggesting substantial bias reduction (Figure 1 ).
Prescriptions for CCBs and Outcomes
During 6 years of follow-up, the primary composite end point of all-cause mortality or HF hospitalization occurred in 82% (666/810) and 81% (655/810) of matched patients with HFpEF receiving and not receiving new discharge prescriptions for CCBs, respectively (hazard ratio when the use of CCBs was compared with their nonuse, 1.03; 95% confidence interval, 0.92-1.14; P=0.638; Figure 2 ; Table 2 ). Because this association was not statistically significant, a formal sensitivity test was not performed. 29 The association between CCB prescription and the primary composite end point was homogeneous across various subgroups of patients, with the exceptions of black patients and patients having coronary artery disease (Figure 3) . CCB users had no significant association with individual end point components of all-cause mortality and hospitalization (Table 2) . Similar associations were observed in matched cohorts of HFpEF patients, defined by EF cutoff 50%.
Among 7514 prematch patients, hazard ratios (95% confidence intervals) for unadjusted, multivariable-adjusted, and propensity-adjusted associations for primary composite end point of all-cause mortality or HF hospitalization with the use of CCBs were 0.96 (0.89-1.04; P=0.352), 1.03 (0.95-1.12; P=0.494), and 1.02 (0.94-1.11; P=0.671; Table 2 ), respectively. Similar associations were observed with individual end point components of all-cause mortality and hospitalization (Table 2) .
Outcomes by CCB Class
Compared with matched patients not receiving CCBs, hazard ratios (95% confidence intervals) for the primary composite end point of all-cause mortality or HF hospitalization Figure 2 . Kaplan-Meier plot for primary composite end point of all-cause mortality or heart failure hospitalization in a propensitymatched inception cohort of older patients with heart failure and preserved ejection fraction, receiving and not receiving a new discharge prescription for calcium channel blockers (CCB). CI indicates confidence interval; HR, hazard ratio. (17) 163 (20) 150 (19) 162 (20) South 2034 (30) 265 (33) 280 (35) 263 (33) West 1392 (21) 150 (18) 156 (19) 150 (19) *Determined by local laboratories. (Table 3) . Corresponding associations for total mortality, HF hospitalization, and all-cause hospitalization were displayed in Table 3 .
Discussion
Findings from the current study demonstrate that in a wide spectrum of propensity-matched balanced cohort of older HFpEF patients, a new discharge prescription of CCBs had no association with the primary composite end point of all-cause mortality or HF hospitalization or with the secondary individual end points of all-cause mortality, HF hospitalization, and all-cause hospitalization. Furthermore, these associations were similar, regardless of whether the class of dihydropyridine (amlodipine) or nondihydropyridine (nonamlodipine) CCB was used.
To the best of our knowledge, this is the first report examining the clinical effectiveness of CCBs in a nationally representative real-world population of HFpEF patients using a rigorously conducted propensity-matched design that provides insights into the role of CCBs in patients with HFpEF. Hypertension is one of the leading causes of HFpEF in older adults, and CCB is one of the commonly prescribed antihypertensive drugs. Because there are currently no evidence-based guideline recommendations for the use of CCBs in HFpEF, these drugs were likely used for the control of BP and heart rate. These findings suggest that the negative inotropic and chronotropic effects of CCBs had no negative association with outcomes in HFpEF. CCBs have been shown to have variable effects on cardiovascular outcomes in HF patients. [30] [31] [32] [33] [34] In the small placebo-controlled crossover trials of older HFpEF patients, a nonamlodipine CCB, verapamil has been shown to improve exercise capacity, HF score, and LV diastolic function without any significant effect on BP and EF. 6, 7 In addition, in patients with cardiomyopathy, verapamil and diltiazem had been shown to significantly improve symptoms by improvements in cardiac function and exercise tolerance. 35, 36 In animal models, dihydropyridines prevent ischemiainduced increases in LV diastolic stiffness and improve diastolic performance in pacing-induced HF. 37 According to AHA/ACC HF guidelines, most of the CCBs should be avoided in patients with heart failure and reduced ejection fraction (HFrEF) because of its negative inotropic effect and adverse cardiovascular events. 4 However, in the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) trial, amlodipine had neutral effects on the longterm clinical outcomes in severe chronic HF patients. 32 Finding from the Survival and Ventricular Enlargement (SAVE) trial suggested that in postmyocardial infarction HFrEF patients, Figure 1 . ‡Adjusted for propensity score which was estimated for each patient in the prematch cohort using nonparsimonious logistic regression model. November 2014 nonrandomized use of CCBs had no association with subsequent cardiovascular outcome. 33 A subgroup analysis of the PRAISE trial, in contrast, demonstrated that amlodipine use was associated with 38% and 45% reduced risk of sudden death and pump failure death, respectively, in those with nonischemic HF. 31 However, the PRAISE II study demonstrated no improvement in clinical outcomes with amlodipine in patients with nonischemic HFrEF. 38 Taken together with findings from RCTs of CCBs in HFrEF, findings from the current study in HFpEF suggest that CCBs do not improve clinical outcomes in HF in general.
Our study has several limitations. We acknowledge that the lack of information about the BP-lowering effect of CCBs in our data set is a limitation. If BP was lower in the CCB group during follow-up, then the equivalent outcome observed may have occurred despite a differential BP levels as BP has been shown to be associated with outcomes in patients with hypertension, although the association is less well established in patients with HF. 14, 39, 40 We had no data on dosages for individual drugs and postdischarge adherence. Substantial crossover during follow-up may result in potential regression dilution and underestimation of true associations, which may, in part, explain the null association observed in our study. However, findings from other studies suggest that the degree of such postdischarge crossover is generally modest and unlikely to completely nullify true associations. 41, 42 As in any observational study, chance, bias, and confounding are potential alternate explanations, but unlikely given the observed null associations. Findings from this study are based on fee-forservice Medicare patients enrolled into OPTIMIZE-HF and may not be generalizable to all Medicare beneficiaries. However, Medicare-linked OPTIMIZE-HF patients have been shown to be characteristically and prognostically similar to HF patients in the general Medicare population. 28 Finally, the data for this study were collected from medical records and depended on the accuracy and completeness of clinical documentation.
In conclusion, in real-world hospitalized older HFpEF patients not receiving prior CCBs, a new discharge prescription for CCBs had no associations with the primary composite end point of total mortality or HF hospitalization and 
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Hazard ratio (95% CI) All-cause mortality or heart failure hospitalization Figure 3 . Association of a new discharge prescription for calcium channel blockers (CCB) with primary composite end point of all-cause mortality or heart failure hospitalization in subgroups of propensity-matched inception cohort of older patients with heart failure and preserved ejection fraction. CI indicates confidence interval.
individual end points of mortality or hospitalization, regardless of the class of CCBs.
